GlucaGen, Baqsimi, Gvoke, Zegalogue
Evidence Grade A — Regulatory approved. 53567 published studies. 1000 registered clinical trials.
Loading...
Glucagon is a natural hormone produced by the pancreas that raises blood sugar when it drops too low. Pharmaceutical versions are used as emergency rescue treatments for severe hypoglycaemia — dangerously low blood sugar episodes that can cause unconsciousness in people using insulin. Recent innovations including a nasal powder (Baqsimi) and ready-to-use auto-injectors (Gvoke, Zegalogue) have made it much easier to administer in emergencies.
53,567 published studies: 28002 human, 18165 animal, 4266 in-vitro, 9538 reviews
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps.
Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
When blood sugar drops too low, your pancreas releases glucagon to trigger the liver to release its stored sugar (glycogen) back into the bloodstream. Pharmaceutical glucagon works the same way — it binds to glucagon receptors on liver cells, triggering rapid release of stored sugar. This can raise blood sugar levels within minutes, which is why it is the primary emergency treatment for severe hypoglycaemia. It also relaxes smooth muscle in the digestive tract, which is why it is used as a diagnostic tool during imaging procedures to temporarily slow gut movement.
Emergency glucagon rescue is well-established and life-saving. The major recent advances have focused on making it easier to use under emergency conditions. Traditional glucagon kits required mixing a powder with liquid before injection — a complex process for someone whose family member is unconscious. Baqsimi (nasal powder, 2019) eliminated needles entirely. Gvoke (auto-injector, 2019) eliminated the mixing step. Dasiglucagon/Zegalogue (stable liquid, 2021) demonstrated 99% glucose recovery within 15 minutes. Beyond emergency rescue, the glucagon receptor has become a major target in obesity and metabolic disease research. Dual agonist drugs that combine glucagon receptor activity with GLP-1 activity (such as survodutide) are in late-stage trials for obesity and liver disease, leveraging glucagon's ability to increase energy expenditure alongside GLP-1's appetite-suppressing effects.
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
Closed-loop Control of Glucose Levels in the Context of Exercise in Adults With Type-1 Diabetes
FDA ORIG 1
FDA SUPPL 3
FDA SUPPL 1
FDA SUPPL 2
FDA ORIG 1
FDA SUPPL 5
FDA ORIG 1
Health Canada Market Authorisation
FDA SUPPL 1
FDA SUPPL 2
FDA ORIG 1
FDA SUPPL 8
FDA SUPPL 9
FDA SUPPL 7
FDA SUPPL 13
FDA SUPPL 13
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 12
FDA SUPPL 4
FDA ORIG 1
FDA SUPPL 24
FDA ORIG 1
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
